#United States #New York #Class Action #Securities Fraud #Capricor Therapeutics

Capricor Therapeutics, Inc. Class Action: What Investors Need to Know

Overview

On August 26, 2025, Levi & Korsinsky, LLP announced a class action lawsuit against Capricor Therapeutics, Inc., focused on securities fraud allegations. The action involves investors adversely affected between October 9, 2024, and July 10, 2025. This news emphasizes the importance for affected shareholders to act quickly, as the deadline to become a lead plaintiff is set for September 15, 2025.

The Allegations

The lawsuit claims that Capricor misled investors regarding its lead cell therapy candidate, deramiocel, which is intended for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD). During the specified period, Capricor reportedly provided positive information about its ability to secure a Biologics License Application (BLA) from the U.S. FDA. However, the firm failed to disclose critical adverse facts regarding the efficacy and safety data from its Phase 2 HOPE-2 trial.

Notably, on July 11, 2025, Capricor issued a press release that it received a Complete Response Letter (CRL) from the FDA, which denied the BLA application. The CRL raised concerns about the lack of substantial evidence indicating the drug's effectiveness. Additionally, it pointed out outstanding items concerning the Chemistry, Manufacturing, and Controls in the application. Following this announcement, Capricor's stock value dropped significantly, signaling the potential financial impact on investors.

Investor Options

If you suffered financial losses during this timeframe due to the alleged misconduct, you have a chance to recover through this class action. Those affected must file a motion to be appointed as a lead plaintiff by the impending September 15, 2025 deadline. Importantly, involvement in this case does not require investors to serve as lead plaintiffs to share in any recovery.

Participation in the class action may result in compensation without incurring out-of-pocket expenses or legal fees, which is a critical aspect for investors concerned about the potential costs of litigation.

Why Choose Levi & Korsinsky?

With over 20 years of experience representing shareholders in complex securities litigation, Levi & Korsinsky has a proven track record of securing substantial settlements for clients. The firm has been recognized by ISS Securities Class Action Services as one of the top securities litigation firms in the United States for seven consecutive years. Their dedicated team of more than 70 professionals is well-equipped to navigate the complexities of the case and advocate effectively on behalf of affected investors.

Contact Information

Victims of the alleged securities fraud can reach out to Joseph E. Levi, Esq. at Levi & Korsinsky via email at [email protected] or by phone at (212) 363-7500. For more details on the class action, including how to file a claim, plaintiffs can refer to the official submission form available online.

Conclusion

As the September 15 deadline approaches, Capricor investors who believe they are eligible to join the class action should not delay their outreach. The potential for recovery lies in understanding and acting on the details of the lawsuit. Investors are encouraged to get informed and consider their options carefully amid the developments surrounding Capricor Therapeutics.